JAK2 and cancer: Another possible explanation is that cancer cells exert genetic mutation in IFN-γ related signaling pathways Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), which make cancer cells less susceptible to T cell-mediated IFN-γ tumor suppression [150,153].